United States · Accelerated approval
FDA accelerated approval of VOCERYQ
FDA grants accelerated approval to VOCERYQ for adults with recurrent respiratory papillomatosis, to reduce the frequency of surgical papilloma excisions.
About this rule
FDA describes VOCERYQ as the first plasmid DNA-based immunotherapy approved in the United States. Its indication is to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis. Continued approval may depend on verification and description of clinical benefit in confirmatory studies. Approval and commercial availability are distinct milestones.
- Agency
- Food and Drug Administration
- Instrument
- VOCERYQ accelerated approval
- Published
- Oct 30, 2026
- Approved
- Oct 30, 2026
Who it affects
INOVIO, clinicians treating adults with recurrent respiratory papillomatosis and teams planning access to the approved treatment.